These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pharmacokinetics and pharmacodynamics of dermatan sulfate after intravenous and intramuscular administration to healthy volunteers. Blardi P, Messa GL, Urso R, Di Perri T. Int J Clin Pharmacol Res; 1993; 13(4):231-8. PubMed ID: 8150550 [Abstract] [Full Text] [Related]
3. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers. Esslinger HU, Haas S, Maurer R, Lassmann A, Dübbers K, Müller-Peltzer H. Thromb Haemost; 1997 May; 77(5):911-9. PubMed ID: 9184402 [Abstract] [Full Text] [Related]
12. Effects of heparin, dermatan sulfate and of their association on the inhibition of venous thrombosis growth in the rabbit. Carrie D, Caranobe C, Gabaig AM, Larroche M, Boneu B. Thromb Haemost; 1992 Dec 07; 68(6):637-41. PubMed ID: 1287877 [Abstract] [Full Text] [Related]
16. Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer. Biesma B, Pokorny R, Kovarik JM, Duffy FA, Willemse PH, Mulder NH, de Vries EG. Cancer Res; 1993 Dec 15; 53(24):5915-9. PubMed ID: 8261403 [Abstract] [Full Text] [Related]
20. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Clin Pharmacol Ther; 2005 Oct 31; 78(4):412-21. PubMed ID: 16198660 [Abstract] [Full Text] [Related] Page: [Next] [New Search]